ArticleFrontiers in microbiology2025
Shiga toxin-producing
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Shiga toxin producing Methods: Epidemiological data from 5,769 cases of STEC infection confirmed during the 7-year period 2016-2022 were reviewed in conjunction with epidemiological typing data from 3,746 case isolates (2,939 analyzed via whole genome sequencing). Results and discussion: Severe illness was reported for 25% of all STEC cases, and 23% of cases were hospitalized. All age groups were affected, but the greatest level of morbidity was observed in those less than 5 years old where the hemolytic uremic syndrome (HUS) incidence rate was 2.86/100,000. Serotypes O157:H7 and O26:H11 together accounted for 54% of infections. Other common serotypes differed from those reported as common elsewhere and included O128:H2, O38:H26, O146:H21 and O91:H14. Shiga toxin subtype 2a strains were more associated with serious illness than other subtypes, regardless of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.